Market Closed -
Euronext Bruxelles
16:35:26 02/05/2024 BST
After market
18:16:39
363.1
EUR
+3.51%
364.4
+0.34%
Argenx : BlackRock Inc. - argenx SE - Breda
November 30, 2022 at 08:24 pm
Back
BlackRock Inc. - argenx SE - Breda
Below you will find information from the register substantial holdings and gross short positions. The information has been provided by the organisation.
Date of transaction 29 nov 2022
Person obliged to notify BlackRock Inc.
Issuing institution argenx SE
Registration Chamber of Commerce 24435214
Place of residence Breda
Previous result
Next result
Distribution in numbers
Type of share
Number of shares
Number of voting rights
Capital interest
Voting rights
Manner of disposal
Settlement
Gewoon aandeel
Number of shares 1.822.578,00
Number of voting rights 2.273.123,00
Capital interest Reëel
Voting rights Reëel
Manner of disposal Middellijk
(BlackRock, Inc.)
Certificaat van aandeel
Number of shares 767.702,00
Number of voting rights 831.197,00
Capital interest Potentieel
Voting rights Potentieel
Manner of disposal Middellijk
(Blackrock, Inc.)
Contract for difference
Number of shares 353,00
Number of voting rights 353,00
Capital interest Potentieel
Voting rights Potentieel
Manner of disposal Middellijk
(BlackRock, Inc.)
Settlement In contanten
Gewoon aandeel
Number of shares 167.445,00
Number of voting rights 172.786,00
Capital interest Potentieel
Voting rights Potentieel
Manner of disposal Middellijk
(BlackRock, Inc.)
Settlement Fysieke levering
Distribution in percentages
Type
Total holding
Directly real
Directly potential
Indirectly real
Indirectly potential
Kapitaalbelang
Total holding 4,99 %
Directly real 0,00 %
Directly potential 0,00 %
Indirectly real 3,29 %
Indirectly potential 1,69 %
Stemrecht
Total holding 5,92 %
Directly real 0,00 %
Directly potential 0,00 %
Indirectly real 4,11 %
Indirectly potential 1,82 %
Date last update: 30 November 2022
Share information
Share on: Share this
Disclaimer
arGEN-X SE published this content on 29 November 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 30 November 2022 20:23:01 UTC .
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading
04-17
MT
Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
04-16
CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading
04-04
MT
Argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease
03-27
CI
Scotiabank Raises Price Target on Argenx SE to $408 From $402, Maintains Sector Perform Rating
03-26
MT
Argenx Gets Japanese Regulator's Approval for Intravenous Use of Vyvgart in Primary Immune Thrombocytopenia
03-26
MT
Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia
03-26
CI
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
03-21
MT
US Futures, European Stocks Rise After Fed Maintains Outlook
03-21
DJ
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading
03-13
MT
Truist Securities Raises Price Target on Argenx to $440 From $370, Maintains Buy Rating
03-05
MT
JMP Securities Adjusts Argenx's Price Target to $471 From $462, Keeps Market Outperform Rating
03-01
MT
Baird Cuts Price Target on Argenx to $490 From $505, Maintains Outperform Rating
03-01
MT
Global markets live: HP, Moncler, Snowflake, Salesforce, Duolingo...
02-29
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading
02-29
MT
Sector Update: Health Care Stocks Advance Premarket Thursday
02-29
MT
Sector Update: Health Care
02-29
MT
Transcript : Argenx SE, Q4 2023 Earnings Call, Feb 29, 2024
02-29
Argenx Q4 Loss Widens, Revenue Increases -- Shares Down Pre-Bell
02-29
MT
Argenx SE Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
02-29
CI
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday
02-20
MT
Argenx Says FDA Accepted for Priority Review Supplemental BLA for Autoimmune Disease Drug Vyvgart Hytrulo
02-20
MT
US FDA Accepts for Priority Review Argenx's Biologics License Application for Vyvgart Hytrulo
02-20
MT
Argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
02-20
CI
Wolfe Research Starts Argenx With Peer Perform Rating
02-15
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
More about the company
Last Close Price
350.8
EUR
Average target price
439.3
EUR
Spread / Average Target
+25.23%
Consensus
1st Jan change
Capi.
+5.71% 22.25B -1.10% 104B +6.95% 97.47B -13.06% 21.68B -9.70% 18.2B -39.98% 17.02B -10.50% 16.36B +8.19% 14.39B +39.70% 12.37B +304.57% 8.43B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1